Macrophage migration inhibitory factor promoter polymorphisms are associated with disease activity in rheumatoid arthritis patients from Southern Mexico
Abstract Background Macrophage migration inhibitory factor (MIF) is a cytokine capable of stimulating inflammatory cytokine and matrix metalloproteinase production from macrophages and synovial fibroblasts, which leads to persistent inflammation and bone degradation, two of the major pathological pr...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Molecular Genetics & Genomic Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/mgg3.1037 |
| _version_ | 1811322794036690944 |
|---|---|
| author | Guillermo Santoscoy‐Ascencio Christian Johana Baños‐Hernández José Eduardo Navarro‐Zarza Jorge Hernández‐Bello Richard Bucala Andres López‐Quintero Emmanuel Valdés‐Alvarado Isela Parra‐Rojas Berenice Illades‐Aguiar José Francisco Muñoz‐Valle |
| author_facet | Guillermo Santoscoy‐Ascencio Christian Johana Baños‐Hernández José Eduardo Navarro‐Zarza Jorge Hernández‐Bello Richard Bucala Andres López‐Quintero Emmanuel Valdés‐Alvarado Isela Parra‐Rojas Berenice Illades‐Aguiar José Francisco Muñoz‐Valle |
| author_sort | Guillermo Santoscoy‐Ascencio |
| collection | DOAJ |
| description | Abstract Background Macrophage migration inhibitory factor (MIF) is a cytokine capable of stimulating inflammatory cytokine and matrix metalloproteinase production from macrophages and synovial fibroblasts, which leads to persistent inflammation and bone degradation, two of the major pathological processes in rheumatoid arthritis (RA). The aim of this study was to evaluate the association of MIF promoter polymorphisms (−794CATT5‐8 rs5844572 and −173G > C, rs755622), circulating MIF levels, and mRNA expression with RA susceptibility and disease activity. Methods A case–control study was conducted in 200 RA patients and 200 control subjects (CS) from Southern Mexico. Genotyping was performed by conventional PCR and PCR‐RFLP methods. MIF mRNA expression was quantified by real‐time PCR and MIF serum levels were determined by an ELISA kit. Results The 7,7 (−794CATT5‐8) and −173CC (−173G > C) genotypes were associated with higher disease activity in RA patients. MIF serum levels were increased, and MIF mRNA expression was reduced in RA patients as compared to CS. In addition, RA patients with moderate disease activity had higher MIF levels than those with low disease activity. The −794CATT5‐8 and −173G > C MIF polymorphisms were not associated with RA susceptibility. Conclusion These results suggest an important role of MIF polymorphisms and MIF serum levels with disease activity in RA. |
| first_indexed | 2024-04-13T13:41:20Z |
| format | Article |
| id | doaj.art-9559627533604ea8a70405770feeda0f |
| institution | Directory Open Access Journal |
| issn | 2324-9269 |
| language | English |
| last_indexed | 2024-04-13T13:41:20Z |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Molecular Genetics & Genomic Medicine |
| spelling | doaj.art-9559627533604ea8a70405770feeda0f2022-12-22T02:44:37ZengWileyMolecular Genetics & Genomic Medicine2324-92692020-01-0181n/an/a10.1002/mgg3.1037Macrophage migration inhibitory factor promoter polymorphisms are associated with disease activity in rheumatoid arthritis patients from Southern MexicoGuillermo Santoscoy‐Ascencio0Christian Johana Baños‐Hernández1José Eduardo Navarro‐Zarza2Jorge Hernández‐Bello3Richard Bucala4Andres López‐Quintero5Emmanuel Valdés‐Alvarado6Isela Parra‐Rojas7Berenice Illades‐Aguiar8José Francisco Muñoz‐Valle9Instituto de Investigación en Ciencias BiomédicasCentro Universitario de Ciencias de la SaludUniversidad de Guadalajara Guadalajara Jalisco MexicoInstituto de Investigación en Ciencias BiomédicasCentro Universitario de Ciencias de la SaludUniversidad de Guadalajara Guadalajara Jalisco MexicoDepartamento de Medicina Interna‐Reumatología Hospital General de Chilpancingo Dr. Raymundo Abarca Alarcón Chilpancingo de los Bravo, Guerrero MexicoInstituto de Investigación en Ciencias BiomédicasCentro Universitario de Ciencias de la SaludUniversidad de Guadalajara Guadalajara Jalisco MexicoDepartment of Medicine/Section of Rheumatology Yale University School of Medicine New Haven CT USAInstituto de Investigación en Ciencias BiomédicasCentro Universitario de Ciencias de la SaludUniversidad de Guadalajara Guadalajara Jalisco MexicoInstituto de Investigación en Ciencias BiomédicasCentro Universitario de Ciencias de la SaludUniversidad de Guadalajara Guadalajara Jalisco MexicoFacultad de Ciencias Químico‐Biológicas Universidad Autónoma de Guerrero Chilpancingo de los Bravo, Guerrero MexicoFacultad de Ciencias Químico‐Biológicas Universidad Autónoma de Guerrero Chilpancingo de los Bravo, Guerrero MexicoInstituto de Investigación en Ciencias BiomédicasCentro Universitario de Ciencias de la SaludUniversidad de Guadalajara Guadalajara Jalisco MexicoAbstract Background Macrophage migration inhibitory factor (MIF) is a cytokine capable of stimulating inflammatory cytokine and matrix metalloproteinase production from macrophages and synovial fibroblasts, which leads to persistent inflammation and bone degradation, two of the major pathological processes in rheumatoid arthritis (RA). The aim of this study was to evaluate the association of MIF promoter polymorphisms (−794CATT5‐8 rs5844572 and −173G > C, rs755622), circulating MIF levels, and mRNA expression with RA susceptibility and disease activity. Methods A case–control study was conducted in 200 RA patients and 200 control subjects (CS) from Southern Mexico. Genotyping was performed by conventional PCR and PCR‐RFLP methods. MIF mRNA expression was quantified by real‐time PCR and MIF serum levels were determined by an ELISA kit. Results The 7,7 (−794CATT5‐8) and −173CC (−173G > C) genotypes were associated with higher disease activity in RA patients. MIF serum levels were increased, and MIF mRNA expression was reduced in RA patients as compared to CS. In addition, RA patients with moderate disease activity had higher MIF levels than those with low disease activity. The −794CATT5‐8 and −173G > C MIF polymorphisms were not associated with RA susceptibility. Conclusion These results suggest an important role of MIF polymorphisms and MIF serum levels with disease activity in RA.https://doi.org/10.1002/mgg3.1037DAS28genetic susceptibilityMIFpolymorphismsrheumatoid arthritis |
| spellingShingle | Guillermo Santoscoy‐Ascencio Christian Johana Baños‐Hernández José Eduardo Navarro‐Zarza Jorge Hernández‐Bello Richard Bucala Andres López‐Quintero Emmanuel Valdés‐Alvarado Isela Parra‐Rojas Berenice Illades‐Aguiar José Francisco Muñoz‐Valle Macrophage migration inhibitory factor promoter polymorphisms are associated with disease activity in rheumatoid arthritis patients from Southern Mexico Molecular Genetics & Genomic Medicine DAS28 genetic susceptibility MIF polymorphisms rheumatoid arthritis |
| title | Macrophage migration inhibitory factor promoter polymorphisms are associated with disease activity in rheumatoid arthritis patients from Southern Mexico |
| title_full | Macrophage migration inhibitory factor promoter polymorphisms are associated with disease activity in rheumatoid arthritis patients from Southern Mexico |
| title_fullStr | Macrophage migration inhibitory factor promoter polymorphisms are associated with disease activity in rheumatoid arthritis patients from Southern Mexico |
| title_full_unstemmed | Macrophage migration inhibitory factor promoter polymorphisms are associated with disease activity in rheumatoid arthritis patients from Southern Mexico |
| title_short | Macrophage migration inhibitory factor promoter polymorphisms are associated with disease activity in rheumatoid arthritis patients from Southern Mexico |
| title_sort | macrophage migration inhibitory factor promoter polymorphisms are associated with disease activity in rheumatoid arthritis patients from southern mexico |
| topic | DAS28 genetic susceptibility MIF polymorphisms rheumatoid arthritis |
| url | https://doi.org/10.1002/mgg3.1037 |
| work_keys_str_mv | AT guillermosantoscoyascencio macrophagemigrationinhibitoryfactorpromoterpolymorphismsareassociatedwithdiseaseactivityinrheumatoidarthritispatientsfromsouthernmexico AT christianjohanabanoshernandez macrophagemigrationinhibitoryfactorpromoterpolymorphismsareassociatedwithdiseaseactivityinrheumatoidarthritispatientsfromsouthernmexico AT joseeduardonavarrozarza macrophagemigrationinhibitoryfactorpromoterpolymorphismsareassociatedwithdiseaseactivityinrheumatoidarthritispatientsfromsouthernmexico AT jorgehernandezbello macrophagemigrationinhibitoryfactorpromoterpolymorphismsareassociatedwithdiseaseactivityinrheumatoidarthritispatientsfromsouthernmexico AT richardbucala macrophagemigrationinhibitoryfactorpromoterpolymorphismsareassociatedwithdiseaseactivityinrheumatoidarthritispatientsfromsouthernmexico AT andreslopezquintero macrophagemigrationinhibitoryfactorpromoterpolymorphismsareassociatedwithdiseaseactivityinrheumatoidarthritispatientsfromsouthernmexico AT emmanuelvaldesalvarado macrophagemigrationinhibitoryfactorpromoterpolymorphismsareassociatedwithdiseaseactivityinrheumatoidarthritispatientsfromsouthernmexico AT iselaparrarojas macrophagemigrationinhibitoryfactorpromoterpolymorphismsareassociatedwithdiseaseactivityinrheumatoidarthritispatientsfromsouthernmexico AT bereniceilladesaguiar macrophagemigrationinhibitoryfactorpromoterpolymorphismsareassociatedwithdiseaseactivityinrheumatoidarthritispatientsfromsouthernmexico AT josefranciscomunozvalle macrophagemigrationinhibitoryfactorpromoterpolymorphismsareassociatedwithdiseaseactivityinrheumatoidarthritispatientsfromsouthernmexico |